December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

33.83 -0.20 (-0.59%)
Streaming Delayed Price Updated: 10:15 AM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
33 34 Next >
News headline image
Catalyst Pharma The No. 1 Biotech, Just Crushed 2023 Guidance Estimates ↗
The guidance includes Catalyst's newest, and second, product. 
Via Investor's Business Daily
News headline image
Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early Settlement
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
7 Core Stocks to Build a Solid Portfolio Around ↗
You’ll enjoy your investing journey more if you know that you can rely on your core of stocks to buy to provide a solid foundation. 
Via InvestorPlace
News headline image
Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Why Teva Pharmaceutical Stock Is Sliding Today ↗
Investors were disappointed with the drugmaker's 2023 outlook. 
Via The Motley Fool
News headline image
Teva Pharmaceutical Stock Dives On Fourth-Quarter Miss, Light 2023 Guidance ↗
The company missed fourth-quarter estimates and issued light guidance. 
Via Investor's Business Daily
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
By Julian Richard, Benzinga 
Via TheNewswire.com
News headline image
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome 
Via News Direct
News headline image
BRTX's ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome ↗
Metabolism is the chemical process whereby the body produces energy from food. By breaking down carbohydrates and fats into sugars, the cells access fuel that can be used or stored via the liver or... 
Via Benzinga
News headline image
Teva to Present at the Barclays Global Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Better Generics Pharmaceutical Stock: Teva or Viatris? ↗
Both have plans to return to growth. 
Via The Motley Fool
News headline image
Teva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior Notes and the Increase of the Maximum Tender Amount of its Debt Tender Offer
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
7 Smart Stock Picks for Cautious Investors ↗
As market volatility continues, consider playing it safe with these seven high-quality stocks for cautious investors. 
Via InvestorPlace
News headline image
Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ Lives
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Walmart, Home Depot And 3 Stocks To Watch Heading Into Tuesday ↗
With US futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
News headline image
Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
A Patent Cliff Is Coming For Bristol — Can Billions In New Products Fill The Gap? ↗
The company's biggest moneymakers are soon to lose patent protection. 
Via Investor's Business Daily
News headline image
Axsome Therapeutics (AXSM) Stock Falls as Teva Pursues Generic Depression Drug ↗
Axsome Therapeutics (AXSM) stock is taking a beating on Monday as rival Teva Pharmaceutical (TEVA) prepares a generic depression drug. 
Via InvestorPlace
News headline image
Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling ↗
The company only just gained approval for its depression drug in August. 
Via Investor's Business Daily
News headline image
Teva Reaches Agreement With Florida to Settle the State’s Price Fixing Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Pharmaceutical Industries (TEVA) Q4 2022 Earnings Call Transcript ↗
TEVA earnings call for the period ending December 31, 2022. 
Via The Motley Fool
News headline image
Teva Pharma Posts Lower Q4 Earnings, FY23 Outlook Within Expectations ↗
 
Via Benzinga
News headline image
Teva Reports Fourth Quarter and Full Year 2022 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Nasdaq Bear Market: 3 Tantalizing Value Stocks That Can Double Your Money by 2026 ↗
These profitable companies are exceptionally cheap and ripe for the picking, following a 33% decline in the Nasdaq Composite. 
Via The Motley Fool
News headline image
The 7 Best Growth Stocks to Buy for February 2023 ↗
Some of the best growth stocks are lesser-known names that have the ability to provide tremendous long-term upside for investors. 
Via InvestorPlace
News headline image
Stock Market Rally Powers Higher Amid Big Earnings From Tesla, Boeing, Microsoft, American Express: Weekly Review ↗
Stocks reacted well to uneven earnings and economic reports. 
Via Investor's Business Daily
News headline image
Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed? ↗
Things aren't as bad as they might seem. 
Via The Motley Fool
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.